Evidence-based Complementary and Alternative Medicine Journal Impact Factor & Information

Publisher: Hindawi Publishing Corporation

Journal description

Evidence-based Complementary and Alternative Medicine (eCAM) is an international, peer-reviewed journal that seeks to understand the sources and to encourage rigorous research in this new, yet ancient world of complementary and alternative medicine. The Journal seeks to apply scientific rigor to the study of complementary and alternative medicine (CAM) modalities, particularly traditional Asian healing systems. eCAM emphasizes health outcome, while documenting biological mechanisms of action. The journal is devoted to the advancement of science in the field of basic research, clinical studies, methodology or scientific theory in diverse areas of Biomedical Sciences.

Current impact factor: 2.18

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 2.175
2012 Impact Factor 1.722
2011 Impact Factor 4.774
2010 Impact Factor 2.964
2009 Impact Factor 2.064
2008 Impact Factor 1.954
2007 Impact Factor 2.535

Impact factor over time

Impact factor

Additional details

5-year impact 2.14
Cited half-life 2.30
Immediacy index 0.41
Eigenfactor 0.01
Article influence 0.37
Website Evidence-based Complementary and Alternative Medicine website
Other titles Evidence-based complementary and alternative medicine (Online), ECAM
ISSN 1741-427X
OCLC 55647292
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details

Hindawi Publishing Corporation

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Publisher's version/PDF may be used
    • Creative Commons Attribution License
    • Eligible UK authors may deposit in OpenDepot
    • All titles are open access journals
  • Classification
    ​ green

Publications in this journal

  • Evidence-based Complementary and Alternative Medicine 05/2015; 2015. DOI:10.1155/2015/206439
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background. Dianthus basuticus is a commonly used medicinal plant in Basotho traditional medicine for the treatment of diabetes,but there is no report on its safety or toxicity.Therefore, we evaluated the toxicity profile of the hydroethanol whole plant extract ofDianthus basuticus in Wistar rats. Methods. Acute toxicity test was performed with single oral administration of 100–3200mg/kg body weight of D. basuticus extract to rats and the animals were observed for 14 days for signs of toxicity. The subacute toxicityexperiment was conducted by oral administration of graded doses (200, 400, and 800mg/kg) of D. basuticus extract daily for 28days. Behavioural changes as well as haematological, biochemical, and histological parameters were then evaluated. Results. There was no observable sign of toxicity in the acute toxicity test. There were significant decreases (𝑃 < 0.05) in the feed and waterintake as well as total cholesterol and triglycerides of the D. basuticus extract-treated rats in subacute toxicity study.There were notreatment related differences in the haematological, biochemical, and histopathological evaluations. Conclusions. Administration of hydroethanol extract of D. basuticus may be safe at the dosages tested in this study but its continuous usage can cause anorexia.
    Evidence-based Complementary and Alternative Medicine 04/2015; 2013:1-10.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Schizophrenia is a serious psychiatric illness with an unclear cause. One theory is that demyelination of white matter is one of the main pathological factors involved in the development of schizophrenia. The current study evaluated the protective effects of Areca catechu nut extract (ANE) on a cuprizone-induced demyelination mouse model. Two doses of ANE (1% and 2%) were administered orally in the diet for 8 weeks. Animals subjected to demyelination showed impaired spatial memory and less social activity. In addition, mice subjected to demyelination displayed significant myelin damage in cortex and demonstrated a higher expression of NG2 and PDGFRα and AMPK activation. ANE treatment not only significantly enhanced cognitive ability and social activity, but also protected myelin against cuprizone toxicity by promoting oligodendrocyte precursor cell (OPC) differentiation. In addition, ANE treatment demonstrated significant dephosphorylation of AMPKα, indicating a regulatory role for ANE in schizophrenia. This study showed that ANE treatment may enhance cognitive ability and social activity by facilitating OPC differentiation and protecting against myelin damage in cortex. Results also suggest the AMPK signaling pathway may be involved in this process.
    Evidence-based Complementary and Alternative Medicine 02/2015; 2015. DOI:10.1155/2015/426092